Debbie Rigby rounds up the latest in research news
Analysis of registry data in GARFIELD‐AF shows moderate‐to‐severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality in patients with newly diagnosed atrial fibrillation. In real world use, the use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA2DS2-VASc score), but not by CKD stage.
Am Heart Assoc. 2019;8:e010510.
Supplementation with 3 different doses of vitamin D3 [12,000 international units (IU), 24,000 IU, or 48,000 IU] given once a month showed no difference in change in BMD at the hip over 12 months between the 3 doses of vitamin D. The treatment was safe and effective in increasing plasma 25(OH)D concentrations, with no dose-related adverse events.
American Journal of Clinical Nutrition 2019;109:207-217.
ACO includes two conditions (smoking asthmatics and eosinophilic COPD patients) with different medication requirement and prognosis that should not be pooled together. Use of ≥300 blood eosinophils/μL as a treatable trait should be recommended.
PLoS One. 2019; 14(1): e0210915.
Single-inhaler triple therapy has the potential to improve adherence, symptom control, and quality of life, and reduce exacerbations. Patients at high risk likely to benefit from escalation to triple therapy from monotherapy or double combination treatment include any one of the following criteria: 1) at least two exacerbations treated with oral corticosteroids, antibiotics, or both in the previous year; 2) at least one severe exacerbation that required hospital admission in the previous year; 3) one exacerbation a year on a repeated basis for 2 consecutive years.
International Journal of COPD 2019:14 391–401.